DIR Return Create A Forum - Home
---------------------------------------------------------
Road2HardCoreIron
HTML https://road2hardcoreiron.createaforum.com
---------------------------------------------------------
*****************************************************
DIR Return to: HGH/ IGF1/ SLIN & Peptides
*****************************************************
#Post#: 6214--------------------------------------------------
The Difference Between (ZPHC, CP, Spectrum) Vs Unlabeled HGH ?
Half Life Increased
By: Road2HardCoreIron Date: July 19, 2025, 9:33 pm
---------------------------------------------------------
ZPHC, Canadalab, and Spectrum half-life. Half is increased up to
58 days once mixed. However, the bac water will start to lose
its potency after 28 days. It should be swapped for a new bac
water after 28 days. This process increases the release of hGH
in your system. Only top-of-the-line peptides are made using
this method. This is why they proudly produce such high dosages
of HGH. Anyone interested in trying these products should seek a
licensed doctor. Get your lab work and learn about what you are
prescribed. What products are included in the medication? The
pros and cons. I'm not a doctor. Nor do we offer this
medication. We are just messengers to ensure you make wise
decisions.
(Big Ronnie Coleman's recent issues with Sepsis) Should be
aware of and care about what goes into our bodies. Whether it
be due to back surgeries or other things. Everyone should know
we are allowing in our bodies and how and where it is produced.
Long-acting forms of growth hormone-releasing hormone and growth
hormone: effects in normal volunteers and adults with growth
hormone deficiency
David R Clemmons 1
Background: Growth hormone (GH) replacement therapy in adults
and children has found broad acceptance by endocrinologists and
patients, but the need for daily injections remains a
significant barrier to more widespread use. LONG-ACTING
FORMULATIONS: Several approaches have been taken to develop
long-acting forms of GH and to extend the half-life of
GH-releasing factor. Each of these preparations has been tested
in experimental animal models and found to extend the half-life
of GH and GH-releasing hormone (GHRH) and to increase mean daily
GH levels. Frequent sampling following administration of
long-acting GHRH showed that the greatest increases occurred in
trough GH levels, which increased 7.8-fold. The extended GH
half-life and increased trough levels resulted in increases in
insulin-like growth factor I (IGF-I) levels, which increased
1.4- to 4.1-fold and extended the duration of the IGF-I increase
from 7 to 14 days. These increases in GH and IGF-I levels allow
these compounds to be administered much less frequently, and
several studies have shown that IGF-I levels can be maintained
in a therapeutically effective range with much less frequent GH
administration.
Safety: Complications other than those generally associated with
GH therapy include nodule formation and lipoatrophy at the
injection sites. One long-term study of a long-acting
formulation demonstrated that growth could be effectively
stimulated in GH-deficient children, but that the peak growth
velocity was only about 80% of that seen following daily
subcutaneous GH injections. Subcutaneous nodule formation in
some patients may have contributed to noncompliance and thus to
the difference in growth velocity.
Conclusions: Different types of GH and GHRH formulations have
been developed with extended half-lives. In general, these
preparations are pharmacokinetically and pharmacodynamically
effective, extend GH half-lives with longer sustained elevation
of IGF-I and permit much less frequent GH administration. Thus,
it may be possible to develop a therapeutically effective form
of GH for use in long-term treatment. The precise efficacy and
safety assessments to use in monitoring long-term GH
administration have not been definitively established.
*****************************************************